Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...

Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

NEW YORK, NY / ACCESS Newswire / March 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Obesity Care Week (OCW) returns for its annual global campaign aimed at raising awareness, educating and advocating for individuals affected by obesity. This year's theme, "Commit to Care," emphasizes ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...